“AmplifyBio is cutting costs, closing its R&D and characterization services site in South San Francisco and laying off employees in its Ohio-based preclinical CRO business, a company spokesperson confirmed to Fierce Biotech in an email.”
All entries for: Cardiology
December 9, 2024
AmplifyBio
Layoffs
West Jefferson, OH
201-500 employees
Disease Area: Cardiology, Neurological Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
April 24, 2024
BioMarin
Discontinued Drug, Discontinued Research, Layoffs
San Rafael, CA
1,001-5,000 employees
As a result of its prioritized portfolio, four programs will be discontinued, including BMN 331, BMN 255, BMN 355 and BMN 365. None of the programs were discontinued due to safety signals.
4 Discontinued Drugs: BMN 331 (biologic), BMN 255 (biologic), BMN 355 (biologic), BMN 365 (biologic)
4 Discontinued Research Programs
Disease Area: Cardiology, Chronic Disease, Multiple, Rare Diseases
Drug Type: Biologic
